# US 2008/0187569 A1 · Dissolution of arterial plaque

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187569 A1
- Document ID: US20080187569A1
- Status: Published application
- Kind: A1
- Application number: 12/024,908
- Filed: 2008-02-01
- Published: 2008-08-07
- Earliest claimed: 2005-11-22
- Assignees: Z & Z Medical Holdings, Inc.
- Inventors: Filiberto ZADINI; Giorgio Zadini
- Web page: https://patentgrep.com/patent/US20080187569A1

## CPC

- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/7023: {Transdermal patches and similar drug-containing composite devices, e.g. cataplasms (galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Embodiments of methods of treating atherosclerosis are described. In some embodiments an emulsifier is provided to achieve levels in the systemic circulation that are effective to solubilize atherosclerotic plaque, resulting in plaque regression. In some embodiments, levels of greater than 50 μM are achieved; in some embodiments levels ranging from about 100 μM to about 600 μM are achieved; in some embodiments, levels ranging from about 100 μM to about 300 μM are achieved. Emulsifiers can include bile salts, saponins, and ionic, nonionic, and zwitterionic detergents, or salts, conjugates, hydrates, solvates, or polymorphs thereof. In some embodiments, a statin can be administered simultaneously or sequentially with an emulsifier.

## Claims

### Claim 1

A method, of treating atherosclerosis in a patient, comprising:
administering, across an epithelium of a patient, a pharmaceutical formulation comprising an emulsifier;
enhancing a permeability of the epithelium to the emulsifier with a permeability enhancer;
wherein enhancing the permeability of the epithelium is effective to result in passage of the emulsifier across the epithelium and into the patient's systemic circulation;
wherein the passage of the emulsifier across the epithelium results in sustained levels of the emulsifier in the patient's systemic circulation that are therapeutically effective to result in regression of an atherosclerotic plaque.

### Claim 2 (depends on 1)

The method of claim 1, wherein the emulsifier comprises at least one of a bile acid, a saponin, a detergent, or pharmaceutically acceptable salts, conjugates, hydrates, solvates, polymorphs, or mixtures thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the emulsifier comprises a bile acid, or pharmaceutically acceptable salts, conjugates, hydrates, solvates, polymorphs, or mixtures thereof.

### Claim 4 (depends on 2)

The method of claim 2, wherein the sustained levels of the emulsifier in the systemic circulation are greater than 50 μM.

### Claim 5 (depends on 2)

The method of claim 2, wherein the sustained levels of the emulsifier in the systemic circulation are in a range between about 50 μM and about 600 μM.

### Claim 6 (depends on 2)

The method of claim 2, wherein the sustained levels of the emulsifier in the systemic circulation are in a range between about 100 μM and about 300 μM.

### Claim 7 (depends on 2)

The method of claim 2, wherein the emulsifier comprises deoxycholic acid.

### Claim 8 (depends on 7)

The method of claim 7, wherein the sustained levels of the deoxycholic acid in the systemic circulation are greater than 50 μM.

### Claim 9 (depends on 7)

The method of claim 7, wherein the sustained levels of the deoxycholic acid in the systemic circulation are in a range between about 50 μM and about 600 μM.

### Claim 10 (depends on 7)

The method of claim 7, wherein the sustained levels of the deoxycholic acid in the systemic circulation are in a range between about 100 μM and about 300 μM.

### Claim 11 (depends on 2)

The method of claim 2, wherein the emulsifier comprises a mixture of ursodeoxycholic acid and deoxycholic acid in substantially equimolar amounts.

### Claim 12 (depends on 2)

The method of claim 2, wherein the emulsifier comprises hyodeoxycholic acid.

### Claim 13 (depends on 12)

The method of claim 12, wherein the sustained levels of the hyodeoxycholic acid in the systemic circulation are greater than about 50 uM.

### Claim 14 (depends on 12)

The method of claim 12, wherein the sustained levels of the hyodeoxycholic acid in the systemic circulation are in a range from about 50 uM to about 600 uM.

### Claim 15 (depends on 12)

The method of claim 12, wherein the sustained levels of the hyodeoxycholic acid in the systemic circulation are in a range from about 100 uM to about 300 uM.

### Claim 16 (depends on 1)

The method of claim 1, wherein the permeability enhancer comprises at least one of a non-ionic detergent, an ionic detergent, and a zwitterionic detergent.

### Claim 17 (depends on 1)

The method of claim 1, wherein the permeability enhancer comprises at least one of iontophoresis, electroporation, sonophoresis, thermal poration, microneedle treatment, and dermabrasion.

### Claim 18 (depends on 1)

The method of claim 1, wherein the pharmaceutical formation is administered intravenously.

### Claim 19 (depends on 1)

The method of claim 1, wherein the pharmaceutical formation is administered intra-arterially.

### Claim 20 (depends on 1)

The method of claim 1, wherein the pharmaceutical formation is administered orally.

### Claim 21 (depends on 1)

The method of claim 1, wherein the pharmaceutical formation is administered sublingually.

### Claim 22 (depends on 1)

The method of claim 1, wherein the pharmaceutical formation is administered transdermally.

### Claim 23 (depends on 1)

The method of claim 1, wherein the pharmaceutical formation is administered via an implantable device.

### Claim 24 (depends on 1)

The method of claim 1, wherein the pharmaceutical formation is administered by injection.

### Claim 25 (depends on 1)

The method of claim 1, wherein the pharmaceutical formation is administered transmucosally.

### Claim 26 (depends on 1)

The method of claim 1, further comprising administering a statin either simultaneously or sequentially with the pharmaceutical formulation.

### Claim 27 (depends on 18)

The method of claim 18, wherein the pharmaceutical formulation further comprises the statin.

### Claim 28

A method of treating atherosclerosis in a patient comprising:
administering a pharmaceutical formulation comprising an emulsifier in an amount effective achieve a concentration of the emulsifier in the systemic circulation of at least 50 μM;
wherein the concentration of the emulsifier in the systemic circulation is sustained for a period of at least two hours;
wherein the concentration of the emulsifier is effective to result in regression of an atherosclerotic plaque.

### Claim 29 (depends on 28)

The method of claim 28, wherein the emulsifier comprises at least one of a bile acid, a saponin, a detergent, or pharmaceutically acceptable salts, conjugates, hydrates, solvates, polymorphs, or mixtures thereof.

### Claim 30 (depends on 28)

The method of claim 28, wherein the emulsifier comprises a bile acid, or pharmaceutically acceptable salts, conjugates, hydrates, solvates, polymorphs, or mixtures thereof.

### Claim 31 (depends on 29)

The method of claim 29, wherein the sustained levels of the emulsifier in the systemic circulation are greater than 50 μM.

### Claim 32 (depends on 29)

The method of claim 29, wherein the sustained levels of the emulsifier in the systemic circulation are in a range between about 50 μM and about 600 μM.

### Claim 33 (depends on 29)

The method of claim 29, wherein the sustained levels of the emulsifier in the systemic circulation are in a range between about 100 μM and about 300 μM.

### Claim 34 (depends on 29)

The method of claim 29, wherein the emulsifier comprises deoxycholic acid.

### Claim 35 (depends on 34)

The method of claim 34, wherein the sustained levels of the deoxycholic acid in the systemic circulation are greater than 50 μM.

### Claim 36 (depends on 34)

The method of claim 34, wherein the sustained levels of the deoxycholic acid in the systemic circulation are in a range between about 50 μM and about 600 μM.

### Claim 37 (depends on 34)

The method of claim 34, wherein the sustained levels of the deoxycholic acid in the systemic circulation are in a range between about 100 μM and about 300 μM.

### Claim 38 (depends on 29)

The method of claim 29, wherein the emulsifier comprises a mixture of ursodeoxycholic acid and deoxycholic acid in substantially equimolar amounts.

### Claim 39 (depends on 29)

The method of claim 29, wherein the emulsifier comprises hyodeoxycholic acid.

### Claim 40 (depends on 39)

The method of claim 39, wherein the sustained levels of the hyodeoxycholic acid in the systemic circulation are greater than about 50 uM.

### Claim 41 (depends on 39)

The method of claim 39, wherein the sustained levels of the hyodeoxycholic acid in the systemic circulation are in a range from about 50 uM to about 600 uM.

### Claim 42 (depends on 39)

The method of claim 39, wherein the sustained levels of the hyodeoxycholic acid in the systemic circulation are in a range from about 100 uM to about 300 uM.

### Claim 43 (depends on 28)

The method of claim 28, further comprising using a permeability enhancer.

### Claim 44 (depends on 43)

The method of claim 43, wherein the permeability enhancer comprises at least one of a non-ionic detergent, an ionic detergent, and a zwitterionic detergent.

### Claim 45 (depends on 28)

The method of claim 28, wherein the permeability enhancer comprises at least one of iontophoresis, electroporation, sonophoresis, thermal poration, microneedle treatment, and dermabrasion.

### Claim 46 (depends on 28)

The method of claim 28, wherein the pharmaceutical formation is administered intravenously.

### Claim 47 (depends on 28)

The method of claim 28, wherein the pharmaceutical formation is administered intra-arterially.

### Claim 48 (depends on 28)

The method of claim 28, wherein the pharmaceutical formation is administered orally.

### Claim 49 (depends on 28)

The method of claim 28, wherein the pharmaceutical formation is administered sublingually.

### Claim 50 (depends on 28)

The method of claim 28, wherein the pharmaceutical formation is administered transdermally.

### Claim 51 (depends on 28)

The method of claim 28, wherein the pharmaceutical formation is administered via an implantable device.

### Claim 52 (depends on 28)

The method of claim 28, wherein the pharmaceutical formation is administered by injection.

### Claim 53 (depends on 28)

The method of claim 28, wherein the pharmaceutical formation is administered transmucosally.

### Claim 54 (depends on 28)

The method of claim 28, further comprising administering a statin either simultaneously or sequentially with the pharmaceutical formulation.

### Claim 55 (depends on 54)

The method of claim 54, wherein the pharmaceutical formulation further comprises the statin.

### Claim 56

A method of treating atherosclerosis in a patient comprising:
administering a pharmaceutical formulation comprising an emulsifier in an amount effective achieve a concentration of the emulsifier in the systemic circulation of at least 50 μM at five minutes after onset of administration;
wherein the concentration of the emulsifier in the systemic circulation is sustained above 50 μM for a period of at least two hours; and
wherein the concentration of the emulsifier is effective to result in regression of an atherosclerotic plaque.

### Claim 57 (depends on 56)

The method of claim 56, wherein the sustained levels of the emulsifier in the systemic circulation are greater than 50 μM.

### Claim 58 (depends on 56)

The method of claim 56, wherein the sustained levels of the emulsifier in the systemic circulation are in a range between about 50 μM and about 600 μM.

### Claim 59 (depends on 56)

The method of claim 56, wherein the sustained levels of the emulsifier in the systemic circulation are in a range between about 100 μM and about 300 μM.
